Importantly, 4SC‐202 inhibited HH/GLI signaling in both, SMOi‐sensitive and SMOi‐resistant settings and interfered with the growth of HH/GLI‐dependent BCC cells in vivo, thereby identifying 4SC‐202 as a promising epigenetic drug for the treatment of HH‐driven cancers. The gene discussed is GLI1; the disease is cancer.